Biocardia announces two scientific abstracts have been accepted at the 2024 technology and heart failure therapeutics conference

Sunnyvale, calif., jan. 31, 2024 (globe newswire) -- biocardia, inc. (“biocardia” or the “company”) (nasdaq: bcda), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, is targeting heart failure and chronic myocardial ischemia as potential indications for its biotherapeutic candidates: autologous cardiamp cell therapy and allogeneic cardiallo cell therapy.
BCDA Ratings Summary
BCDA Quant Ranking